WO2024154003 - DISTINCTIVE IDENTIFICATION AND USE OF A LIQUID BIOPSY CANCER BIOMARKER FOR CANCER DETECTION, MANAGEMENT AND TREATMENT
National phase entry is expected:
Publication Number
WO/2024/154003
Publication Date
25.07.2024
International Application No.
PCT/IB2024/000032
International Filing Date
17.01.2024
Title **
[English]
DISTINCTIVE IDENTIFICATION AND USE OF A LIQUID BIOPSY CANCER BIOMARKER FOR CANCER DETECTION, MANAGEMENT AND TREATMENT
[French]
IDENTIFICATION DISTINCTIVE ET UTILISATION D'UN BIOMARQUEUR DE CANCER PAR BIOPSIE LIQUIDE POUR LA DÉTECTION, LA PRISE EN CHARGE ET LE TRAITEMENT DU CANCER
Applicants **
RARECELLS INC.
Inventors
PATERLINI, Patrizia
Priority Data
63/480,220
17.01.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2466 | |
| EPO | Filing, Examination, Granting | 12719 | |
| Japan | Filing, Examination, Granting | 2422 | |
| South Korea | Filing, Examination, Granting | 2444 | |
| USA | Filing, Examination, Granting | 5140 |
Total:
25,191
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Methods for the distinctive identification and characterization of Cancer Giant Cells, which have a size of 15 microns or more (major axis), which express abnormally high amounts of telomerase, and/or which express syncytin and/or cancer associated antigens and Giant Cells associated antigens such as macrophage antigens which distinguish them from non-cancer Giant Cells. Use of Cancer Giant Cells as a liquid biopsy biomarker to determine the presence of cancer, early detection of cancer, early detection of cancer recurrence, determination of therapy and of treatment response. Use of the Cancer Giant Cells liquid biopsy biomarker for determining the risk of having cancer or cancer recurrence or of being at risk of developing cancer or cancer recurrence, and for treating the subject with personalized therapy against cancer to treat or prevent cancer or cancer recurrence. A kit for detecting Cancer Giant Cells and its use to detect cancer and cancer recurrence and manage cancer treatment is disclosed.[French]
Procédés d'identification et de caractérisation distinctives de cellules cancéreuses géantes, qui ont une taille d'au moins 15 microns (axe principal), qui expriment des quantités anormalement élevées de télomérase et/ou qui expriment de la syncytine et/ou des antigènes associés au cancer et des antigènes associés à des cellules géantes tels que des antigènes de macrophages qui les distinguent des cellules géantes non cancéreuses. Utilisation de cellules cancéreuses géantes comme biomarqueur de biopsie liquide pour déterminer la présence d'un cancer, la détection précoce du cancer, la détection précoce de la récidive du cancer, la détermination de la thérapie et de la réponse au traitement. Utilisation du biomarqueur de biopsie liquide de cellules cancéreuses géantes pour déterminer le risque d'avoir un cancer ou une récidive d'un cancer ou d'être à risque de développer un cancer ou une récidive de cancer, et pour traiter le sujet avec une thérapie personnalisée contre le cancer pour traiter ou prévenir un cancer ou une récidive de cancer. Kit de détection de cellules cancéreuses géantes et son utilisation pour détecter un cancer et une récidive de cancer et gérer le traitement du cancer.